We investigated the hypoglycemic and hypolipidemic effects of two hesperertin glycosides, namely, hesperidin and cyclodextrin (CD)-clathrated hesperetin, in GotoKakizaki (GK) weanling rats with type 2 diabetes. We demonstrated that hesperidin and CD-hesperetin normalized glucose metabolism by altering the activities of glucose-regulating enzymes and reducing the levels of lipids in the serum and liver of the GK rats. These effects of hesperidin glycosides were partly produced by altering the expression of genes encoding the peroxisome proliferator-activated receptors, 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, and the lowdensity lipoprotein receptor.
Diabetes is the most common serious metabolic disorder; it is considered to be one of the five leading causes of death in the world. 1) Hyperglycemia can be initially treated with oral agents and insulin therapy; insulin therapy is occasionally required to achieve target glycemic levels. Diabetes is associated with an increased risk of thrombotic, atherosclerotic, and cardiovascular diseases.
2) Dyslipidemia is a frequent complication of diabetes and is characterized by a low level of highdensity lipoprotein (HDL) cholesterol and high levels of low-density lipoprotein (LDL) cholesterol and triglycerides (TG). Hyperlipidemia is also a metabolic complication of both clinical and experimental diabetes. Flavonoids are present in several types of vegetables and fruits, and it has been suggested that flavonoids are associated with potential health benefits. 3, 4) Hesperidin, a citrus bioflavonoid, exhibits such biological and pharmacological properties as anti-inflammatory, anticarcinogenic, antioxidative, and lipid-lowering activities. [5] [6] [7] Hesperidin also leads to a decrease in the serum and liver cholesterol levels, which is to some extent probably because of the decreased activities of hepatic 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase and acyl CoA:cholesterol acyltransferase (ACAT) and the increased levels of fecal cholesterol. 8) However, the in vivo effects of hesperidin and cyclodextrin (CD)-clathrated hesperetin in type 2 diabetic rats are yet to be elucidated. Moreover, the mechanism underlying the inhibitory effects of hesperidin on lipid metabolism in type 2 diabetic rats remains unclear. In the present study, we investigated the hypoglycemic and hypolipidemic effects of hesperidin and CD-hesperetin in Goto-Kakizaki (GK) rats with type 2 diabetes. Native hesperidin and hesperetin, which is the aglycone of hesperidin, are typical hydrophobic compounds. Since clathration by CD enhances hesperetin solubility, the bioavailability of CD-hesperetin can be expected to be higher than that of native hesperetin.
Six 3-week-old male Wistar rats (Clea Japan, Tokyo, Japan) and eighteen 3-week-old male GK rats (Clea Japan, Tokyo, Japan) were individually housed in stainless-steel rat cages maintained at 22 C under a 12-h light/dark cycle. The study was approved by the Tokyo University of Agriculture Animal Use Committee, and the animals were maintained in accordance with the guidelines recommended by the university for the care and use of laboratory animals. During the 3-d acclimatization period, all rats were fed with a control diet based on the American Institute of Nutrition (AIN)-93G diet; this diet was prepared with corn oil instead of soybean oil. After the acclimatization period, the rats were randomly assigned to the following four experimental groups comprising six rats each: Wistar control (W) group, GK control (GK) group, GK þ 1% hesperidin (H) group, and GK þ 4:6% CD-hesperetin (CH) group. The amount of 1% hesperidin and of 4.6% CDhesperetin was adjusted by corn starch in the respective diet. As an aglycone, the amount of administered hesperetin was the same in the both H and CH groups. In the W, GK, and H groups, the rats were pair-fed their respective diets with those in the CH group. During the feeding term, all rats were provided free access to distilled water. After 4 weeks of feeding, the rats were sacrificed, and their blood and liver samples were collected and used for analysis. The blood samples were y To whom correspondence should be addressed. Fax: +81-3-5477-2658; E-mail: mari@nodai.ac.jp Abbreviations: ACAT, acyl CoA:cholesterol acyltransferase; CD, cyclodextrin; GK, Goto-Kakizaki; GKase, glucokinase; GLUT, glucose transporter; G6Pase, glucose-6-phosphatase; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HMG-CoA, 3-hydroxy-3-methyl-glutarylCoA; PPAR, peroxisome proliferator-activated receptor; TG, triglyceride; TC, total cholesterol centrifuged, and each resulting supernatant was used as a serum sample. Urine was collected during the 24 h before dissection, and the serum and urine samples were stored at À80 C until needed for analyses. The liver was perfused with a cold 0.9% NaCl solution which was then removed. The blood glucose concentration was measured every week. Samples were collected from the tail vein after the animals had been fasted for 12 h, and the glucose concentration was measured with a blood glucose meter (Medisafe-mini GR-102; Terumo Co., Tokyo, Japan). The serum levels of insulin and adiponectin, and the serum and hepatic levels of lipids were measured by using commercial kits (rat insulin ELISA kit and mouse/rat high-molecular-weight adiponectin ELISA kit (Shibayagi, Gunma, Japan); cholesterol C-test, triglyceride E-test, and HDL-cholesterol test (Wako Pure Chemicals, Osaka, Japan)). The Folch method for the extraction of total lipids was used for pretreating the liver.
9) The serum hesperetin concentration was measured by using high-performance liquid chromatography (HPLC) according to a previously described method.
7) The glucokinase (GKase) activity in liver microsomes was measured according to the method described by Davidson and Arion, 10) and the glucose-6-phosphatase (G6Pase) activity was determined according to the method described by Bickerstaff and Burchell. 11) Total RNA was isolated from the homogenized liver samples using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's specifications. The amount and purity of RNA were assessed by spectrophotometry. Firststrand cDNA was reverse transcribed by using a highcapacity cDNA reverse transcription kit with RNase inhibitor (Applied Biosystems, Foster City, CA, USA). The reaction mixture for the TaqMan real-time polymerase chain reaction (PCR) was prepared with the TaqMan gene expression master mix (Applied Biosystems, Foster City, CA, USA), and TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA) for the rat peroxisome proliferator-activated receptor-(PPAR-) (assay ID: Rn 00566193 m1), rat PPAR-(assay ID: Rn 00440945 m1), rat HMG-CoA reductase (assay ID: Rn 00565598 m1), rat ACAT1 (assay ID: Rn 00579605 m1), rat ACAT2 (assay ID: Rn 00596636 m1), rat LDL receptor (assay ID: Rn 00598442 m1), and rat -actin (assay ID: Rn 00667869 m1) were performed. Real-time PCR was conducted with a StepOne real-time PCR system (Applied Biosystems, Foster City, CA, USA). The mRNA expression of PPAR-, PPAR-, HMG-CoA reductase, ACAT1, ACAT2, and the LDL receptor was normalized to that of -actin.
The results are expressed as the mean (standard error of the mean (SEM)) for each group of six rats. After a one-way analysis of variance (ANOVA), Fisher's protected least significant difference (PLSD) test was used to analyze differences between the groups. A p value of less than 0.05 is considered as statistically significant.
The initial body weight and food intake during the feeding period did not differ between the four groups ( Table 1 ). The final body weight was significantly lower in the CH group than in the other three groups because of diarrhea due to CD (Table 1 ). There was no significant difference in the liver weight among the four groups (W, 51:89 AE 4:49; GK, 47:38 AE 1:84; H, 43:38 AE 1:33; CH, 51:06 AE 1:46 (g/kg body wt)). After 1 week, the blood glucose levels were significantly higher in the GK and H groups than in the W and CH groups. However, after 2, 3, and 4 weeks, the blood glucose level was significantly lower in the H group than that in the GK group (Table 1) . The serum insulin level was the highest in the GK group (Table 1) . There was no significant difference in the serum insulin level between the W, H, and CH groups. The serum hesperetin concentration was significantly higher in the CH group than in the H group. Hesperetin was not detected in the other two groups (Table 1) . Many studies have shown that some flavonoids decreased the blood glucose levels and increased the serum insulin concentration. [3] [4] [5] Alterations in the activities of the key enzymes involved in glucose metabolism may be one of the reasons for flavonoids having an ameliorative effect on diabetes. It has been reported that hesperidin and naringin increased the mRNA level of GKase, a key enzyme in glucose catabolism, and decreased the level of G6Pase, a gluconeogenic enzyme, in the liver of C57BL/KsJ-db/ db mice with type 2 diabetes. 12) In this present study, the hepatic GKase activity was higher and G6Pase activity was lower in the GK rats than in the Wistar rats (Table 1) . On the other hand, the activities of both enzymes were normalized and the insulin level was high in the rats that consumed the hesperidin or CDhesperetin diet (Table 2) ; these results have been previously reported for type 2 diabetic mice but not for type 2 diabetic rats. Obesity occurred in C57BL/ KsJ-db/db mice with type 2 diabetes but not in GK rats with type 2 diabetes. It appears that GK rats are more appropriate for use as models of type 2 diabetes for the Japanese. Adiponectin, a metabolically active protein secreted by adipocytes, plays an important role in the regulation of glucose and lipid metabolism, and modifies the insulin sensitivity and energy balance. 13, 14) The serum insulin level in the GK rats increased and the blood glucose level decreased after hesperidin or CDhesperetin administration. Furthermore, the serum adiponectin concentration was significantly low in the GK rats; however, after the hesperidin or CD-hesperetin administration, the serum adiponectin concentration was normalized (Table 1) . We observed in the present study on rodents the in vivo hypoglycemic and hypolipidemic effects of hesperidin mediated by adiponectin when present in the serum in a-high concentration. Liu et al. have demonstrated that naringenin and hesperetin upregulated the transcription of adiponectin and induced the expression of PPAR--controlled luciferase in vitro; 15) however, they were unable to demonstrate the same in vivo. In this present study, the mRNA levels of PPAR-and PPAR-in the H and CH groups were significantly higher and tended to remain high as compared to those in the W and GK groups (Table 3) . Lie et al. did not observe PPAR-activation from treatment with hesperetin in 3T3L1 cells; 15) however, we observed a higher mRNA expression level of PPARin the hesperidin-administered rats than in the control rats. These results suggest that hesperidin and CDhesperetin have exerted their hypoglycemic effect partly through up-regulation of the genes coding for PPARs. Up-regulation of the mRNA expression of PPARs might have improved insulin-resistance by regulating GKase and G6Pase in this study. Since we did not demonstrate the mRNA expressions of adiponectin and PPARs in adipocytes, the interaction in this study of adiponectin and PPARs remains unclear. Regarding glucose transporter (GLUT) 4, which can normalize blood glucose by stimulating the glucose uptake in skeletal muscle and adipocytes, it is well known that flavonoids affect the functions of GLUT 4. 16, 17) Further studies should be conducted to identify the effects of hesperetin glycosides on adiponectin and PPARs in adipocytes and on GLUT 4 in skeletal muscle and adipocytes.
We also observed in this study the hypolipidemic effects of hesperidin and CD-hesperetin on GK rats. The serum concentrations of TG and total cholesterol (TC) were significantly increased in the GK rats; however, the increase in the serum levels of TG and TC was suppressed by hesperidin or CD-hesperetin ( Table 2 ). The ratio of the serum HDL cholesterol level to the serum TC level was lower in the GK group than in the other groups ( Table 2 ). The hepatic TG and TC concentrations were also significantly increased in the GK group; however, in the H and CH groups, the increase in TG and TC levels was suppressed by hesperidin or CD-hesperetin (Table 2) . Furthermore, the serum concentrations of TG and TC in the CH group were significantly lower than those in the H group (Table 2 ), because the serum hesperetin level was higher in the CH group than in the H group.
It is well known that in most animal species, including humans, HMG-CoA reductase inhibitors are very effective in lowering the plasma cholesterol level and these inhibitors are now widely used as statins, i.e., hypocholesterolemic drugs. Bok et al. have demonstrated in rats that naringin and hesperidin significantly lowered the plasma and hepatic levels of cholesterol and TG by inhibiting HMG-CoA reductase and ACAT. 8, 18) Inhibitors of hepatic HMG-CoA reductase, a key enzyme in cholesterol synthase, are widely used as drugs in the treatment of hypercholesterolemia; thus, these inhibitors decrease the incidence of dyslipidemia in diabetic subjects. 19) ACAT is another key cholesterol-regulating enzyme involved in the esterification and absorption of cholesterol, secretion of hepatic LDL-cholesterol, and cholesterol accumulation in the arterial wall. 20) Furthermore, hesperidin enhances the expression of the gene encoding the LDL receptor. 21) These are some possible mechanisms underlying the hypolipidemic effects of hesperidin. We measured the mRNA expression levels of HMG-CoA reductase, ACAT, and the LDL receptor. The mRNA expression level of HMG-CoA reductase was significantly lower in the H and the CH groups than that in the GK group (Table 3) . In contrast, the mRNA level of the LDL receptor was significantly higher in the H and CH groups than that in the GK group (Table 3) . These results suggest that hesperidin or CD-hesperetin induced a hypocholesterolemic effect by inhibiting the expression of hepatic HMG-CoA reductase and activating the LDL receptor. Two ACAT isoenzymes, ACAT-1 and ACAT-2, have been identified in mammals. Tissue distribution studies have shown that the expression of the ACAT-1 message and protein was ubiquitous, whereas the expression of the ACAT-2 message was restricted to the liver and small intestine. 22) In hepatocyte-like HepG2 cells, ACAT-1 comprises 85-90% of the total ACAT activity, with the remainder attributed to ACAT-2. 22) In this study, there were no significant differences in the mRNA levels of ACAT1 and ACAT2 between the four groups ( Table 3) . We also demonstrated an increase in the level of adiponectin which can reduce lipid accumulation after a hesperidin or CDhesperetin administration.
With regard to the difference between the effects of native hesperidin and CD-hesperetin, the blood glucose level after 1 week and the serum levels of TC and TG were lower in the rats that were administered CDhesperetin than in those that were administered native hesperidin. The serum level of hesperetin increased after CD-hesperetin administration; this was not observed in the rats that were administered native hesperidin. Yamada et al. have reported that glucosyl hesperidin was absorbed more rapidly and efficiently than native hesperidin because the former is highly water soluble. 23) CD-hesperetin is also highly water soluble. Furthermore, since CD is a non-digestible sugar, fermentation in the colon may have enhanced the enterohepatic recirculation of hesperetin. A further study may be necessary to compare the ability of CD with or without hesperetin glycosides.
In conclusion, we demonstrated in weanling GK rats that hesperidin and CD-hesperetin normalize the blood glucose level by altering the activities of glucoseregulating enzymes and lowering the serum and liver lipid levels. These hypoglycemic and hypolipidemic effects of hesperidin and CD-hesperetin were produced in type 2 diabetic rats partly by altering the expression of genes encoding PPARs, HMG-CoA reductase, and the LDL receptor.
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